<p>肯尼迪資本管理公司在最近向證券交易委員會（SEC）提交的 13F 文件中披露，其在 Scholar Rock Holding Corporation（NASDAQ:SRRK - 免費報告）中的持股在第二季度增加了 596.4%。該機構投資者在此期間額外購買了 46,722 股後，持有該公司 54,556 股股票。到最近一個季度末，肯尼迪資本管理公司大約擁有 Scholar Rock 0.06% 的股份，價值 1,932,000 美元。</p>
<ul>
<li>3 只被低估的股票在本財報季有反彈潛力</li>
</ul>
<p>其他機構投資者最近也調整了對該公司的持股。英維斯科有限公司在第二季度將其在 Scholar Rock 的持股增加了 12.8%。英維斯科有限公司目前擁有 61,964 股該公司的股票，價值 2,195,000 美元，此前在此期間又購買了 7,027 股。施羅德投資管理集團在第二季度將其在 Scholar Rock 的持股增加了 217.1%。施羅德投資管理集團目前擁有 191,998 股該公司的股票，價值 6,801,000 美元，此前在上個季度又購買了 131,458 股。挪威銀行在第二季度購買了價值約 41,628,000 美元的 Scholar Rock 新頭寸。Elevation Point Wealth Partners LLC 在第二季度獲得了約 94,000 美元的 Scholar Rock 新頭寸。最後，Inceptionr LLC 在第二季度購買了價值約 205,000 美元的 Scholar Rock 新股份。目前，91.08% 的股票由機構投資者持有。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位研究分析師對該股票發表了評論。派珀·桑德勒在 9 月 24 日的研究報告中將 Scholar Rock 的目標價格從 52.00 美元下調至 51.00 美元，並對該公司給予 “增持” 評級。美國銀行在 10 月 9 日的研究報告中開始覆蓋 Scholar Rock。他們對該股票給予 “買入” 評級，目標價格為 53.00 美元。傑富瑞金融集團在 8 月 21 日的研究報告中開始覆蓋 Scholar Rock。他們對該公司設定了 “買入” 評級和 50.00 美元的目標價格。Leerink Partners 在 9 月 15 日的研究報告中將 Scholar Rock 的評級提升至 “強力買入”。最後，Leerink Partners 在 9 月 15 日的研究報告中開始覆蓋 Scholar Rock。他們對該公司設定了 “跑贏大盤” 評級和 51.00 美元的目標價格。四位分析師對該股票給予 “強力買入” 評級，十一位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價格為 48.33 美元。</p>
<p><strong>查看我們對 SRRK 的最新股票分析</strong></p>
<h2>Scholar Rock 內部活動</h2>
<p>在相關消息中，董事 Katie Peng 在 9 月 16 日的交易中出售了 1,006 股 Scholar Rock 股票。該股票以平均價格 32.53 美元出售，總交易額為 32,725.18 美元。出售後，該董事直接持有 33,914 股公司股票，價值 1,103,222.42 美元。此交易代表其持股減少了 2.88%。該交易已在證券交易委員會的文件中披露，具體信息可通過此鏈接查看。此外，董事 Srinivas Akkaraju 在 10 月 3 日的交易中購買了 387,414 股該公司的股票。該股票以每股平均價格 37.27 美元收購，總價值為 14,438,919.78 美元。交易完成後，該董事持有 387,414 股公司股票，價值約 14,438,919.78 美元。此交易代表其持股增加了∞。有關此次購買的更多細節可在官方 SEC 披露中找到。內部人士在上個季度共出售了 143,999 股公司股票，價值 6,411,535 美元。內部人士持有 13.30% 的股票。</p>
<h2>Scholar Rock 股價下跌 0.4%</h2>
<p>NASDAQ SRRK 週一開盤價為 45.02 美元。該公司的市值為 45.9 億美元，市盈率為-14.29，貝塔值為 0.60。Scholar Rock Holding Corporation 的 12 個月低點為 22.71 美元，12 個月高點為 46.98 美元。該公司的速動比率為 6.30，流動比率為 6.30，債務股本比率為 0.41。該公司的 50 日移動平均線為 35.09 美元，200 日移動平均線為 34.51 美元。</p>
<p>Scholar Rock（NASDAQ:SRRK - 獲取免費報告）最近在 11 月 14 日發佈了其財報。該公司報告本季度每股收益（EPS）為-0.90 美元，低於市場共識預期的-0.88 美元，差距為 0.02 美元。在去年同期，該公司每股收益為-0.66 美元。整體來看，賣方分析師預計 Scholar Rock Holding Corporation 在當前財年將發佈-2.42 美元的每股收益。</p>
<h2>Scholar Rock 公司簡介</h2>
<p>（免費報告）</p>
<p>Scholar Rock Holding Corporation 是一家生物製藥公司，專注於發現、開發和交付用於治療嚴重疾病的藥物，這些疾病中蛋白質生長因子的信號傳導起着基礎性作用。該公司開發了 Apitegromab，這是一種抑制肌肉生長因子激活的藥物，目前正在進行針對脊髓性肌萎縮症的第三階段臨牀試驗；以及 SRK-181，該藥物已完成針對對檢查點抑制劑療法（如抗 PD-1 或抗 PD-L1 抗體療法）耐藥癌症的第一階段臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過 Scholar Rock</li>
<li>賣空 - 利弊分析</li>
<li>Rubrik 的巨大反彈：為什麼下一輪上漲可能會很快</li>
<li>能源和石油股票解析</li>
<li>Five Below 和 Dollar Tree 的財報信號顯示消費者轉變</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>Ulta 的股票可能會迎來反彈——20% 的上漲空間？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JSSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JSSw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Scholar Rock 嗎？</h2>
<p>在考慮投資 Scholar Rock 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Scholar Rock 並不在名單上。</p>
<p>雖然 Scholar Rock 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

SRRK

<p>肯尼迪資本管理公司在第二季度將其在 Scholar Rock Holding Corporation 的持股增加了 596.4%，目前持有 54,556 股，價值 193 萬美元。其他機構投資者也調整了他們的持股。分析師對該股票給予了 “買入” 評級，平均目標價格為 48.33 美元。還報告了內部交易活動，包括股票的買賣。Scholar Rock 的股票開盤價為 45.02 美元，市值為 45.9 億美元</p>

<p>Kennedy Capital Management LLC raised its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 596.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,556 shares of the company's stock after acquiring an additional 46,722 shares during the period. Kennedy Capital Management LLC owned approximately 0.06% of Scholar Rock worth $1,932,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>肯尼迪資本管理公司在最近向證券交易委員會（SEC）提交的 13F 文件中披露，其在 Scholar Rock Holding Corporation（NASDAQ:SRRK - 免費報告）中的持股在第二季度增加了 596.4%。該機構投資者在此期間額外購買了 46,722 股後，持有該公司 54,556 股股票。到最近一個季度末，肯尼迪資本管理公司大約擁有 Scholar Rock 0.06% 的股份，價值 1,932,000 美元。</p>
</div><ul>
<li>3 Beaten-Down Stocks With Rebound Potential This Earnings Season</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的股票在本財報季有反彈潛力</li>
</ul>
</div><p>Other institutional investors have also recently modified their holdings of the company. Invesco Ltd. increased its position in shares of Scholar Rock by 12.8% in the second quarter. Invesco Ltd. now owns 61,964 shares of the company's stock worth $2,195,000 after purchasing an additional 7,027 shares during the period. Schroder Investment Management Group grew its stake in Scholar Rock by 217.1% during the second quarter. Schroder Investment Management Group now owns 191,998 shares of the company's stock worth $6,801,000 after buying an additional 131,458 shares in the last quarter. Norges Bank bought a new position in Scholar Rock in the 2nd quarter valued at about $41,628,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Scholar Rock in the 2nd quarter valued at approximately $94,000. Finally, Inceptionr LLC bought a new stake in shares of Scholar Rock during the 2nd quarter worth approximately $205,000. 91.08% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者最近也調整了對該公司的持股。英維斯科有限公司在第二季度將其在 Scholar Rock 的持股增加了 12.8%。英維斯科有限公司目前擁有 61,964 股該公司的股票，價值 2,195,000 美元，此前在此期間又購買了 7,027 股。施羅德投資管理集團在第二季度將其在 Scholar Rock 的持股增加了 217.1%。施羅德投資管理集團目前擁有 191,998 股該公司的股票，價值 6,801,000 美元，此前在上個季度又購買了 131,458 股。挪威銀行在第二季度購買了價值約 41,628,000 美元的 Scholar Rock 新頭寸。Elevation Point Wealth Partners LLC 在第二季度獲得了約 94,000 美元的 Scholar Rock 新頭寸。最後，Inceptionr LLC 在第二季度購買了價值約 205,000 美元的 Scholar Rock 新股份。目前，91.08% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research analysts have commented on the stock. Piper Sandler lowered their price objective on shares of Scholar Rock from $52.00 to $51.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, September 24th. Bank of America began coverage on Scholar Rock in a research note on Thursday, October 9th. They issued a &#34;buy&#34; rating and a $53.00 price target on the stock. Jefferies Financial Group started coverage on Scholar Rock in a research report on Thursday, August 21st. They set a &#34;buy&#34; rating and a $50.00 price objective for the company. Leerink Partnrs raised Scholar Rock to a &#34;strong-buy&#34; rating in a research note on Monday, September 15th. Finally, Leerink Partners began coverage on Scholar Rock in a research note on Monday, September 15th. They set an &#34;outperform&#34; rating and a $51.00 target price for the company. Four analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $48.33.</p>
<div class="lb-trans"><p>幾位研究分析師對該股票發表了評論。派珀·桑德勒在 9 月 24 日的研究報告中將 Scholar Rock 的目標價格從 52.00 美元下調至 51.00 美元，並對該公司給予 “增持” 評級。美國銀行在 10 月 9 日的研究報告中開始覆蓋 Scholar Rock。他們對該股票給予 “買入” 評級，目標價格為 53.00 美元。傑富瑞金融集團在 8 月 21 日的研究報告中開始覆蓋 Scholar Rock。他們對該公司設定了 “買入” 評級和 50.00 美元的目標價格。Leerink Partners 在 9 月 15 日的研究報告中將 Scholar Rock 的評級提升至 “強力買入”。最後，Leerink Partners 在 9 月 15 日的研究報告中開始覆蓋 Scholar Rock。他們對該公司設定了 “跑贏大盤” 評級和 51.00 美元的目標價格。四位分析師對該股票給予 “強力買入” 評級，十一位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價格為 48.33 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on SRRK</strong></p>
<div class="lb-trans"><p><strong>查看我們對 SRRK 的最新股票分析</strong></p>
</div><h2>Insider Activity at Scholar Rock</h2>
<div class="lb-trans"><h2>Scholar Rock 內部活動</h2>
</div><p>In related news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total transaction of $32,725.18. Following the sale, the director directly owned 33,914 shares in the company, valued at $1,103,222.42. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director Srinivas Akkaraju purchased 387,414 shares of the firm's stock in a transaction on Friday, October 3rd. The stock was acquired at an average price of $37.27 per share, with a total value of $14,438,919.78. Following the completion of the transaction, the director owned 387,414 shares in the company, valued at approximately $14,438,919.78. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 143,999 shares of company stock worth $6,411,535 in the last quarter. 13.30% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Katie Peng 在 9 月 16 日的交易中出售了 1,006 股 Scholar Rock 股票。該股票以平均價格 32.53 美元出售，總交易額為 32,725.18 美元。出售後，該董事直接持有 33,914 股公司股票，價值 1,103,222.42 美元。此交易代表其持股減少了 2.88%。該交易已在證券交易委員會的文件中披露，具體信息可通過此鏈接查看。此外，董事 Srinivas Akkaraju 在 10 月 3 日的交易中購買了 387,414 股該公司的股票。該股票以每股平均價格 37.27 美元收購，總價值為 14,438,919.78 美元。交易完成後，該董事持有 387,414 股公司股票，價值約 14,438,919.78 美元。此交易代表其持股增加了∞。有關此次購買的更多細節可在官方 SEC 披露中找到。內部人士在上個季度共出售了 143,999 股公司股票，價值 6,411,535 美元。內部人士持有 13.30% 的股票。</p>
</div><h2>Scholar Rock Trading Down 0.4%</h2>
<div class="lb-trans"><h2>Scholar Rock 股價下跌 0.4%</h2>
</div><p>NASDAQ SRRK opened at $45.02 on Monday. The company has a market cap of $4.59 billion, a price-to-earnings ratio of -14.29 and a beta of 0.60. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $46.98. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The business's fifty day moving average is $35.09 and its 200 day moving average is $34.51.</p>
<div class="lb-trans"><p>NASDAQ SRRK 週一開盤價為 45.02 美元。該公司的市值為 45.9 億美元，市盈率為-14.29，貝塔值為 0.60。Scholar Rock Holding Corporation 的 12 個月低點為 22.71 美元，12 個月高點為 46.98 美元。該公司的速動比率為 6.30，流動比率為 6.30，債務股本比率為 0.41。該公司的 50 日移動平均線為 35.09 美元，200 日移動平均線為 34.51 美元。</p>
</div><p>Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the company posted ($0.66) earnings per share. As a group, sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Scholar Rock（NASDAQ:SRRK - 獲取免費報告）最近在 11 月 14 日發佈了其財報。該公司報告本季度每股收益（EPS）為-0.90 美元，低於市場共識預期的-0.88 美元，差距為 0.02 美元。在去年同期，該公司每股收益為-0.66 美元。整體來看，賣方分析師預計 Scholar Rock Holding Corporation 在當前財年將發佈-2.42 美元的每股收益。</p>
</div><h2>Scholar Rock Profile</h2>
<div class="lb-trans"><h2>Scholar Rock 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.</p>
<div class="lb-trans"><p>Scholar Rock Holding Corporation 是一家生物製藥公司，專注於發現、開發和交付用於治療嚴重疾病的藥物，這些疾病中蛋白質生長因子的信號傳導起着基礎性作用。該公司開發了 Apitegromab，這是一種抑制肌肉生長因子激活的藥物，目前正在進行針對脊髓性肌萎縮症的第三階段臨牀試驗；以及 SRK-181，該藥物已完成針對對檢查點抑制劑療法（如抗 PD-1 或抗 PD-L1 抗體療法）耐藥癌症的第一階段臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Scholar Rock</li>
<li>Short Selling - The Pros and Cons</li>
<li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li>
<li>Energy and Oil Stocks Explained</li>
<li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Scholar Rock</li>
<li>賣空 - 利弊分析</li>
<li>Rubrik 的巨大反彈：為什麼下一輪上漲可能會很快</li>
<li>能源和石油股票解析</li>
<li>Five Below 和 Dollar Tree 的財報信號顯示消費者轉變</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>Ulta 的股票可能會迎來反彈——20% 的上漲空間？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JSSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SRRK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Scholar Rock Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Scholar Rock 嗎？</h2>
</div><p>Before you consider Scholar Rock, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Scholar Rock 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Scholar Rock 並不在名單上。</p>
</div><p>While Scholar Rock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Scholar Rock 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kennedy Capital Management LLC 在 Scholar Rock Holding Corporation $SRRK 中持有價值 193 萬美元的頭寸